RVPH
Reviva Pharmaceuticals Holdings, Inc. NASDAQ Listed Oct 18, 2018$0.86
After hrs
$0.79
-0.93%
Mkt Cap $2.9M
52w Low $0.59
1.2% of range
52w High $23.20
50d MA $1.65
200d MA $7.24
P/E (TTM)
-0.2x
EV/EBITDA
0.7x
P/B
0.0x
Debt/Equity
0.1x
ROE
-229.7%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
0.64
50d MA
$1.65
200d MA
$7.24
Avg Volume
558.1K
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
19925 Stevens Creek Boulevard · Cupertino, CA 95014 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -1.08 | -0.72 | +33.3% | 0.66 | +3.0% | +10.6% | +11.0% | -11.1% | -1.1% | +10.0% | — |
| Nov 13, 2025 | AMC | -0.11 | -0.06 | +45.5% | 10.82 | -3.9% | -7.2% | -3.8% | +10.0% | -6.3% | -3.6% | — |
| Aug 14, 2025 | AMC | -0.15 | -0.12 | +20.0% | 9.32 | +5.2% | +15.9% | -3.9% | +2.9% | -2.8% | +0.2% | — |
| May 15, 2025 | AMC | -0.21 | -0.13 | +38.1% | 16.78 | -1.1% | -2.3% | +8.5% | +16.9% | -4.8% | +6.1% | — |
| Mar 31, 2025 | AMC | -0.22 | -0.15 | +31.8% | 19.08 | -1.5% | -34.9% | -9.6% | +0.4% | -5.9% | +13.2% | — |
| Nov 14, 2024 | AMC | -0.23 | -0.25 | -8.7% | 24.20 | -0.8% | -6.6% | +12.4% | -0.8% | -3.2% | +1.6% | — |
| Aug 14, 2024 | AMC | -0.28 | -0.26 | +7.1% | 14.36 | +0.3% | -4.6% | -6.0% | +24.2% | +42.5% | -25.7% | — |
| May 14, 2024 | AMC | -0.28 | -0.25 | +10.7% | 36.60 | -1.6% | -6.6% | +0.0% | -2.3% | -7.8% | -14.9% | — |
| Apr 15, 2024 | AMC | -0.35 | -0.35 | +0.0% | 69.60 | -4.0% | -4.3% | -3.9% | -5.6% | +0.0% | +2.3% | — |
| Nov 14, 2023 | AMC | -0.35 | -0.44 | -25.7% | 109.70 | +0.3% | -8.8% | -8.5% | -12.3% | +5.0% | +5.9% | — |
| Aug 14, 2023 | AMC | -0.29 | -0.55 | -89.7% | 83.40 | -0.2% | +2.4% | -6.3% | +0.5% | +2.7% | +0.2% | — |
| May 15, 2023 | AMC | -0.36 | -0.30 | +16.7% | 159.80 | -8.0% | -3.1% | +3.1% | -5.4% | -3.3% | -3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Maxim Group | Downgrade | Buy → Hold | — | $0.78 | $0.80 | +2.3% | +0.9% | +7.0% | -8.8% | +12.7% | -1.4% |
| Mar 31 | Roth Capital | Maintains | Buy → Buy | — | $0.66 | $0.68 | +3.0% | +10.6% | +11.0% | -11.1% | -1.1% | +10.0% |
| Mar 30 | Alliance Global Partners | Maintains | Buy → Buy | — | $0.74 | $0.75 | +1.8% | -11.0% | +10.6% | +11.0% | -11.1% | -1.1% |
| Mar 5 | D. Boral Capital | Downgrade | Buy → Hold | — | $4.89 | $4.70 | -3.9% | -13.5% | -15.6% | -19.3% | -9.4% | +7.7% |
| Jan 5 | Chardan Capital | Maintains | Buy → Buy | — | $6.20 | $6.40 | +3.2% | +6.9% | -2.6% | +7.1% | +5.8% | -7.1% |
| Dec 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.80 | $6.33 | -46.4% | -45.5% | -13.5% | +10.4% | -5.5% | -4.1% |
| Dec 23 | D. Boral Capital | Maintains | Buy → Buy | — | $11.80 | $6.33 | -46.4% | -45.5% | -13.5% | +10.4% | -5.5% | -4.1% |
| Nov 19 | D. Boral Capital | Maintains | Buy → Buy | — | $10.63 | $10.66 | +0.3% | -6.3% | -3.6% | +6.8% | +3.1% | -4.2% |
| Oct 28 | D. Boral Capital | Maintains | Buy → Buy | — | $11.83 | $11.60 | -1.9% | -2.4% | +1.6% | +3.0% | -0.8% | -1.6% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.51 | $12.00 | -11.2% | -12.4% | -2.4% | +1.6% | +3.0% | -0.8% |
| Sep 19 | D. Boral Capital | Maintains | Buy → Buy | — | $8.39 | $5.30 | -36.8% | -36.5% | +15.4% | -6.7% | +2.6% | +0.2% |
| Sep 15 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $8.85 | $8.80 | -0.6% | -2.4% | -8.2% | +2.0% | +3.7% | -36.5% |
| Aug 18 | D. Boral Capital | Maintains | Buy → Buy | — | $10.80 | $10.80 | +0.0% | -3.9% | +2.9% | -2.8% | +0.2% | +3.6% |
| Aug 18 | Roth Capital | Maintains | Buy → Buy | — | $10.80 | $10.80 | +0.0% | -3.9% | +2.9% | -2.8% | +0.2% | +3.6% |
| Aug 15 | Maxim Group | Maintains | Buy → Buy | — | $9.32 | $9.80 | +5.2% | +15.9% | -3.9% | +2.9% | -2.8% | +0.2% |
| Jun 27 | D. Boral Capital | Maintains | Buy → Buy | — | $7.16 | $7.68 | +7.3% | -5.7% | +12.9% | -3.0% | +4.2% | -6.5% |
| Jun 3 | D. Boral Capital | Maintains | Buy → Buy | — | $17.60 | $17.40 | -1.1% | -7.3% | -0.1% | -1.8% | +2.7% | +2.9% |
| May 20 | D. Boral Capital | Maintains | Buy → Buy | — | $17.80 | $18.00 | +1.1% | +16.9% | -4.8% | +6.1% | -1.9% | +6.8% |
| Apr 24 | D. Boral Capital | Maintains | Buy → Buy | — | $17.25 | $17.40 | +0.9% | +4.3% | -5.0% | +1.8% | +0.7% | +1.5% |
| Apr 1 | D. Boral Capital | Maintains | Buy → Buy | — | $19.08 | $18.80 | -1.5% | -34.9% | -9.6% | +0.4% | -5.9% | +13.2% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.00 | $40.40 | +1.0% | -3.0% | -2.6% | +1.1% | -4.7% | -2.7% |
| Jan 21 | D. Boral Capital | Maintains | Buy → Buy | — | $35.40 | $36.60 | +3.4% | +13.0% | -3.0% | -2.6% | +1.1% | -4.7% |
| Jan 10 | Maxim Group | Upgrade | Hold → Buy | — | $37.40 | $39.40 | +5.3% | +0.5% | +1.6% | -17.3% | +14.6% | -1.7% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $25.00 | $25.40 | +1.6% | -3.2% | -6.6% | +12.4% | -0.8% | -3.2% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $26.40 | $26.00 | -1.5% | -5.3% | -3.2% | -6.6% | +12.4% | -0.8% |
| Aug 26 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $19.38 | $19.00 | -2.0% | +2.5% | +0.1% | +1.6% | +5.0% | +5.7% |
| Aug 16 | Maxim Group | Downgrade | Buy → Hold | — | $13.70 | $13.40 | -2.2% | -6.0% | +24.2% | +42.5% | -25.7% | +6.2% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.40 | $23.00 | -1.7% | +8.5% | -2.4% | -1.6% | -1.6% | +0.0% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.40 | $27.20 | -0.7% | -1.5% | -7.4% | +2.4% | -1.6% | -0.8% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.00 | $28.60 | -1.4% | +2.8% | +1.3% | -0.7% | -2.7% | -0.7% |
| May 28 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $30.60 | $26.00 | -15.0% | -9.8% | -2.9% | +2.2% | +0.0% | +9.5% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.40 | $61.00 | +1.0% | +2.3% | -1.0% | -1.3% | -1.3% | +0.3% |
| Apr 16 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $69.60 | $66.80 | -4.0% | -4.3% | -3.9% | -5.6% | +0.0% | +2.3% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $57.80 | $58.80 | +1.7% | +8.7% | +22.0% | +1.8% | -3.1% | -10.6% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $86.00 | $86.80 | +0.9% | +2.1% | -3.2% | +1.9% | +0.9% | -0.5% |
| Dec 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $92.80 | $94.20 | +1.5% | +9.9% | +0.8% | -2.5% | +2.8% | +3.1% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $109.80 | $112.40 | +2.4% | -14.6% | -8.4% | +14.6% | -1.2% | +9.0% |
| Oct 30 | Roth MKM | Maintains | Buy → Buy | — | $75.00 | $100.20 | +33.6% | +46.4% | -14.6% | -8.4% | +14.6% | -1.2% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $85.40 | $84.20 | -1.4% | -6.3% | +0.5% | +2.7% | +0.2% | +8.2% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $116.60 | $117.20 | +0.5% | -1.2% | -2.8% | +3.0% | -0.3% | +1.9% |
| Jun 8 | Benchmark | Maintains | Speculative Buy → Buy | — | $143.20 | $144.60 | +1.0% | -0.1% | -4.2% | -7.9% | +2.9% | -4.5% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $171.00 | $166.80 | -2.5% | -2.2% | +0.4% | +1.2% | -6.7% | -7.3% |
| May 3 | Maxim Group | Maintains | Buy → Buy | — | $142.20 | $144.80 | +1.8% | +9.7% | +7.6% | +1.9% | -2.2% | +0.4% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.00 | $89.20 | -0.9% | -1.8% | +1.4% | +1.1% | +2.4% | -2.8% |
| Jan 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $85.40 | $85.60 | +0.2% | +3.7% | -0.5% | -1.1% | -0.7% | +9.9% |
| Nov 1 | Maxim Group | Maintains | Buy → Buy | — | $78.40 | $83.20 | +6.1% | +0.0% | +8.4% | +6.4% | +11.3% | +15.5% |
| Nov 1 | Alliance Global Partners | Maintains | Buy → Buy | — | $78.40 | $83.20 | +6.1% | +0.0% | +8.4% | +6.4% | +11.3% | +15.5% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.60 | $37.20 | +7.5% | +8.7% | -1.6% | -6.5% | -6.9% | +1.9% |
| Jul 26 | Maxim Group | Maintains | Buy → Buy | — | $76.60 | $81.80 | +6.8% | +7.6% | -11.9% | +1.1% | -1.9% | -2.8% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
RVPH disclosed IP strategy efforts to extend brilaroxzine's value and advance development, suggesting management confidence in the program's commercial potential and potential near-term catalysts for investors.
Apr 15
8-K
Unknown — 8-K Filing
Reviva is progressing through late-stage clinical development with FDA guidance, positioning it for potential regulatory catalysts that could drive stock appreciation if trials succeed, though development-stage biotech carries significant execution risk.
Mar 30
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
RVPH secured a $9.0 million financing deal through a placement agency agreement, providing capital for operations or growth without immediate dilution concerns if structured as debt rather than equity.
Mar 19
8-K · 8.01
!! High
Reviva Pharmaceuticals Holdings, Inc. -- 8-K 8.01: Material Event / Announcement
Reviva Pharmaceuticals Holdings remains listed on Nasdaq Capital Market, though the filing suggests reviewing risk factors in conjunction with this disclosure regarding potential market or operational developments.
Mar 5
Data updated apr 26, 2026 11:44pm
· Source: massive.com